Clinical Trials
338
32 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1956
Active, not recruiting
23
6.8%
Completed
216
63.9%
Enrolling By Invitation
2
0.6%
Not yet recruiting
7
2.1%
Recruiting
27
8.0%
Terminated
44
13.0%
Withdrawn
19
5.6%
No approval data available
- A JAMA Oncology analysis of 11,681 US cancer trials (2008–2024) found industry sponsored 81.9% of studies, while federally funded trials disproportionately addressed rare, pediatric, and multimodality research questions. - Federally sponsored trials more often investigated dose de-escalation, non-drug interventions, and combination regimens, whereas industry trials favored single-agent treatments and phase I/III designs. - A separate evaluation of 1,378 federally sponsored trials showed median drug costs exceeded $7.5 million, rising to $11.08 million for federally led studies and nearly $60 million for phase 3 trials. - Researchers warn that reliance on industry for drug supply may limit the types of questions federally funded investigators can ask, underscoring the need for policy innovations to reduce costs.
- Researchers identified anti-Müllerian hormone (AMH) as a blood biomarker that more accurately predicts chemotherapy benefit than age or menopausal status in women under 55 with hormone receptor-positive, HER2-negative breast cancer. - In the RxPONDER trial analysis of 1,556 women, those with AMH levels ≥10 pg/mL saw a 54% reduction in invasive disease recurrence risk with chemotherapy (HR=0.46), while those below the threshold derived no benefit. - Approximately one in five premenopausal women had AMH levels low enough to potentially safely forgo chemotherapy and its associated toxicities. - The findings suggest measuring ovarian reserve via ultrasensitive AMH and inhibin B assays should become part of shared decision-making before adjuvant therapy selection.
- A multicenter clinical trial demonstrated that 71% of desmoplastic melanoma patients treated with pembrolizumab before surgery had no detectable cancer remaining at the time of operation. - The SWOG S1512 study represents the first trial to test neoadjuvant PD-1 blockade in this rare and aggressive skin cancer population, offering an alternative to extensive surgical procedures. - At three-year follow-up, 95% of patients had not died from the disease and 74% remained cancer-free, marking a significant shift in treatment approach for this challenging condition.
- Osel Inc. has partnered with SWOG Cancer Research Network to conduct the first pivotal Phase 3 trial of a microbiome-based oral therapy in oncology, testing MO-03 in combination with immunotherapy for advanced renal cell carcinoma. - The BIOFRONT trial will enroll approximately 700 patients across 150 U.S. sites and builds on prior studies showing statistically significant improvements in response rates and progression-free survival without added toxicity. - MO-03 is a high-potency formulation of Clostridium butyricum Miyairi 588 developed specifically for oncology, with Osel holding exclusive marketing rights in the United States, Canada, and Europe. - The National Cancer Institute-supported trial is scheduled to begin in Q1 2026 and could position MO-03 as the first-in-class live biotherapeutic product approved for cancer treatment.
- The DART trial (NCI/SWOG S1609) represents the largest immunotherapy study in rare cancer patients, demonstrating that combination nivolumab plus ipilimumab maintains efficacy regardless of prior anti-PD-1/PD-L1 exposure. - Brain metastases patients showed comparable safety and activity profiles with the combination immunotherapy, challenging the common practice of excluding these patients from clinical trials. - The multicenter basket trial provides crucial evidence that rare cancer patients with brain metastases need and can benefit from immunotherapy treatment options.
- BostonGene and SWOG Cancer Research Network launched the PRISM study, a randomized Phase II trial evaluating biomarker-directed therapy for extensive stage small cell lung cancer patients. - The NCI-supported trial will enroll up to 900 patients and use BostonGene's AI-powered multiomics platform to identify molecular subtypes and assign personalized treatments. - Current standard treatment extends overall survival by only 2-3 months, with most patients experiencing disease progression despite combination chemotherapy and immunotherapy. - The study builds on previous SWOG S1929 trial findings that demonstrated promising improvements in progression-free survival using targeted approaches based on four distinct SCLC molecular subtypes.
- A multi-institutional study published in Science Direct demonstrates that urine-based tumor DNA (utDNA) testing can predict which bladder cancer patients face higher recurrence risk after immunotherapy treatment. - Researchers analyzed utDNA from 89 patients in the SWOG S1605 trial using the UroAmp test, finding that positive utDNA results correlated with poorer treatment response and increased cancer recurrence rates. - The study offers potential for personalized bladder cancer care by enabling earlier identification of treatment response, potentially reducing unnecessary surgeries and improving patient outcomes. - This approach could help tailor therapy decisions sooner for the approximately 83,000 Americans diagnosed with bladder cancer annually, particularly those with high-risk disease unresponsive to BCG treatment.
- Financial hardship affects 50-70% of cancer patients in community settings, leading to treatment adherence issues and worse outcomes, particularly among underserved populations. - Social determinants of health contribute to a 20% higher cancer mortality rate in underserved populations, with factors like food, housing, and transportation insecurity creating significant barriers to care. - Miami Cancer Institute implements innovative solutions including bilingual patient navigation, community partnerships, and expanded clinical trial access to bridge the cancer care gap for underrepresented populations.
- The PROSPECT-Lung trial is evaluating whether immunotherapy is more effective when administered before or after surgery for resectable non-small cell lung cancer. - This pragmatic trial aims to reflect real-world treatment decisions and provide clearer guidance on integrating immunotherapy into lung cancer treatment regimens. - The study will enroll 1,100 patients across multiple sites in the United States and is led by the Alliance for Clinical Trials in Oncology and the SWOG Cancer Research Network. - PROSPECT-Lung is the first trial to open through the NCI's Clinical Trials Innovation Unit, designed to accelerate cancer treatment development.
- The FDA has updated the labeling for fludarabine phosphate, expanding its approved use in treating B-cell chronic lymphocytic leukemia (CLL). - Fludarabine phosphate is now indicated for CLL patients as part of combination regimens and for those who have progressed on alkylating agents. - The updated label includes revised dosage recommendations when fludarabine phosphate is used with cyclophosphamide and rituximab. - The label update also highlights potential risks, such as neurological toxicities and myelosuppression, and provides dosage guidelines for combination therapies.
